IP Library Granted Patent US 7,144,732
Granted Patent B2
US 7,144,732 · App. 10/835,517 · Granted Dec 5, 2006

Vertebrate embryonic pattern-inducing proteins and uses related thereto

Assignees: President and Fellows of Harvard College; Imperial Cancer Research Technology Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,144,732
App. No.
10/835,517
Granted
Dec 5, 2006
Kind
B2
Abstract

The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.

Claims (27)

1. A method for modulating one or more of growth, differentiation, or survival of an embryonic mammalian cell responsive to hedgehog, comprising treating the cell with an effective amount of a hedgehog polypeptide thereby altering, relative to the cell in the absence of hedgehog treatment, at least one of (i) rate of growth, (ii) differentiation, or (iii) survival of the cell, and wherein said hedgehog polypeptide binds to a hedgehog receptor and promotes hedgehog signaling, and wherein said hedgehog polypeptide is a Sonic hedgehog polypeptide or an N-terminal autoproteolytic fragment thereof.

2. The method of claim 1 , which polypeptide comprises the amino acid sequence designated in any of SEQ ID No:11, SEQ ID No:13, or an N-terminal proteolytic fragment thereof.

3. The method of claim 2 , which polypeptide is an N-terminal autoproteolytic fragment of said hedgehog polypeptide.

4. The method of claim 1 , wherein the cell is a osteogenic cell, and the polypeptide modulates osteogenesis.

5. The method of claim 1 , wherein the cell is a chondrogenic cell, and the polypeptide modulates chondrogenesis.

6. A method for modulating one or more of growth, differentiation, or survival of an embryonic mammalian neuronal cell responsive to hedgehog, comprising treating the cell with an effective amount of a hedgehog polypeptide thereby altering, relative to the cell in the absence of hedgehog treatment, at least one of (i) rate of growth, (ii) differentiation, or (iii) survival of the cell, and wherein said hedgehog polypeptide binds to a hedgehog receptor and promotes hedgehog signaling, and wherein said hedgehog polypeptide is a Sonic hedgehog polypeptide or an N-terminal autoproteolytic fragment thereof.

7. The method of claim 6 , which neuronal cells are selected from any of motor neurons, cholinergic neurons, dopanergic neurons, serotenergic neurons, and peptidergic neurons.

8. The method of claim 6 , wherein the polypeptide promotes survival of the neuronal cells.

9. A method for modulating, in an embryo, cell growth, cell differentiation or cell survival, comprising administering an effective amount of a hedgehog polypeptide to alter, relative to in the absence of administration of a hedgehog polypeptide, at least one of (i) rate of growth, (ii) differentiation, or (iii) survival of one or more cell-types in the embryo, wherein the hedgehog polypeptide binds to a hedgehog receptor and promotes hedgehog signaling, and wherein said hedgehog polypeptide is a Sonic hedgehog polypeptide or an N-terminal autoproteolytic fragment thereof.

10. The method of claim 9 , which polypeptide comprises an amino acid sequence identical to the amino acid sequence designated in any of SEQ ID No:11, SEQ ID No:13, or an N-terminal auto-proteolytic fragment thereof.

11. The method of claim 10 , which polypeptide is an N-terminal auto-proteolytic fragment of said hedgehog polypeptide.

12. The method of claim 9 , which method modulates osteogenesis in the embryo.

13. The method of claim 9 , which method modulates chondrogenesis in the embryo.

14. The method of claim 9 , which method modulates differentiation or survival of neuronal cells in the embryo.

15. A method for inducing an embryonic cell to differentiate to a neuronal cell phenotype, comprising contacting said cell with an amount of a hedgehog polypeptide effective to induce differentiation to a neuronal cell phenotype, wherein said hedgehog polypeptide binds to a hedgehog receptor and promotes hedgehog signaling, and wherein said hedgehog polypeptide is a Sonic hedgehog polypeptide or an N-terminal autoproteolytic fragment thereof.

16. The method of claim 13 , which polypeptide comprises an amino acid sequence identical to the amino acid sequence designated in any of SEQ ID No:11, SEQ ID No:13, or an N-terminal auto-proteolytic fragment thereof, wherein said polypeptide binds to a hedgehog receptor and promotes hedgehog signaling.

17. The method of claim 14 , which polypeptide is an N-terminal auto-proteolytic fragment of said hedgehog polypeptide.

18. The method of claim 15 , wherein said neuronal cell phenotype is selected from any of motor neurons, cholinergic neurons, dopanergic neurons, serotenergic neurons, and peptidergic neurons.

19. The method of claim 15 , further comprising contacting said cell with an effective amount of a growth factor having neurotrophic activity.

20. The method of claim 19 , wherein said growth factor is selected from any of a nerve growth factor, cilliary neurotrophic growth factor, schwanoma-derived growth factor, glial growth factor, striatal-derived neuronotrophic factor, platelet-derived growth factor.

21. The method of claim 2 , which polypeptide comprises an amino acid sequence identical to the amino acid sequence designated in SEQ ID No:13 or an N-terminal auto-proteolytic fragment thereof.

22. The method of claim 9 , which polypeptide comprises an amino acid sequence identical to the amino acid sequence designated in SEQ ID No:13 or an N-terminal auto-proteolytic fragment thereof.

23. The method of claim 14 , which polypeptide comprises an amino acid sequence identical to the amino acid sequence designated in SEQ ID No:13 or an N-terminal auto-proteolytic fragment thereof.

24. The method of claim 1 , wherein said cell is a cell in culture and said method is an in vitro method.

25. The method of claim 2 , wherein said cell is a cell in culture and said method is an in vitro method.

26. The method of claim 15 , wherein said cell is a cell in culture and said method is an in vitro method.

27. The method of claim 16 , wherein said cell is a cell in culture and said method is an in vitro method.

Assignments (1)
CONFIRMATORY LICENSE Recorded Dec 1, 2009
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023584/0987 →
Continuity (6)
Continuation 0895477100 · Oct 20, 1997
Continuation 0846238600 · Jun 5, 1995
Continuation In Part 0843509300 · May 4, 1995
Continuation In Part 0835606000 · Dec 14, 1994
Continuation In Part 0817642700 · Dec 30, 1993
Related Publication 20050004028A1 · Jan 6, 2005